This article has been updated to include share prices and details.
NEW YORK, Oct. 29 (GenomeWeb News) - Shares in Lynx Therapeutics were down nearly 9 percent at $2.65 in mid-afternoon trade on the Nasdaq exchange after sliding to $2.25 earlier in the day on news that its financial position is more precarious than originally reported.
Registering provides access to this and other free content.
Already have an account?Login Now.
A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.
The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.
In Nature this week: investigation into the genetics of medulloblastoma, and more
A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.